Axsome reports strong AUVELITY-led growth as pipeline advances

Transcript intelligence

What changed

Compared with the prior-quarter analysis, the supplied Q2 analysis showed continued AUVELITY momentum, including early Alzheimer’s agitation adoption, FDA acceptance of the AXS-12 NDA, and broader Phase III progress. The analysis also identified no new guidance and noted that current EPS and revenue were below consensus.

Guidance delta

No new guidance was provided in the supplied analysis; management emphasized continued commercial expansion and pipeline execution.

Key takeaways

• Q2 revenue increased 46% year over year to $218 million, led by a 51% increase in AUVELITY sales.
• AUVELITY’s Alzheimer’s agitation launch showed a 126% quarter-over-quarter increase in new-to-brand prescriptions among patients 65 and older.
• The company highlighted FDA acceptance of the AXS-12 NDA and progress across several Phase III programs.
• Cash remained around $320 million, while higher SG&A accompanied sales-force expansion and marketing activity.

Management priorities

• Expand AUVELITY, including the Alzheimer’s agitation indication and potential direct-to-consumer advertising.
• Advance Phase II/III and Phase III programs across AXS-05, solriamfetol, AXS-14, AXS-20, and AXS-17.
• Continue pursuing market-access gains and work toward the company’s stated goal of approximately one new NDA filing per year through 2030.